Greenwich LifeSciences Q3 2026 Earnings Date & Estimates

Greenwich LifeSciences (NASDAQ:GLSI) is a clinical-stage biotechnology company focused on developing immunotherapies designed to reduce the risk of breast cancer recurrence. The company’s lead product candidate is GLSI-100, an investigational vaccine combining the HER2-derived peptide GP2 with granulocyte-macrophage colony-stimulating factor (GM-CSF).

GLSI-100 is being developed as an adjuvant therapy for patients with HER2-positive breast cancer who have completed standard treatment, including trastuzumab. The treatment is intended to stimulate an immune response against cells expressing HER2 and help prevent disease recurrence. The company has advanced the candidate through clinical development, including the Phase IIb PRESENT trial, and has been pursuing a Phase III development program.

Greenwich LifeSciences was founded by Snehal Patel, who serves as the company’s chief executive officer. The company is headquartered in Houston, Texas, and its activities have centered on the clinical development of GLSI-100 for breast cancer rather than the marketing of approved products. Its investigational programs and clinical studies have primarily focused on patients and research sites in the United States.